Momenta Pharmaceuticals, Inc. (MNTA)

[RockRat]

Inasmuch as MNTA's poster suggests sonic hedgehog inhibition as the likely MOA for reduced primary tumor growth & metastasis/invasion in pancreatic cancer, could we benefit from the potential success of GDC-0449, Curis' HH inhibitor being developed now by Genentech/Roche?

I haven't followed that program closely, believe it's already approved for BCC or some such, and is being trialed by several entities in pancreatic cancer. I would expect readouts from these trials in advance of readouts from M402's trial. Perhaps a date range has been given by Curis or their partners? Maybe I'll take a quick look tomorrow if no one else does, unless someone convinces me beforehand it's not worth the effort.

I would guess the safety profiles are somewhat different. With M402, I gather the main concern so far is how well they engineered out the anticoagulant properties. Haven't looked recently at GDC-0449, and don't remember a thing about its tox profile.

edit: I see some readout here at AACR recently. Getting sleepy, will read tomorrow . . .

http://seekingalpha.com/article/670801-curis-new-data-shows-efficacy-in-advanced-pancreatic-cancer

Regards, RockRat